Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
13.4 CHF
−1.08 M CHF
0.00 CHF
5.45 M
About HBM N
Sector
Industry
CEO
Andreas Wicki
Website
Headquarters
Zug
Founded
2001
ISIN
CH0012627250
FIGI
BBG000BM1N33
As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.